To assess the possible role of digitalis in the etiology of arrhythmia following cardiopulmonary bypass, serum digoxin or digitoxin was determined serially by radioimmunoassay in 24 chronically digitalized patients undergoing open-heart surgery. After an initial fall during bypass probably secondary to intraoperative fluid, serum digitalis rebounded, rising to or surpassing the preoperative value in 21 of the 24 patients studied. Peak rebound serum digitalis occurred an average of 13 hours following onset of bypass. Eight patients receiving maintenance digoxin developed arrhythmia postbypass at or near the peak of the rebound. The arrhythmia subsided as the peak was passed. Mean serum digoxin at the time of arrhythmia was 1.3 0.2 (SD) ng/ml. A significantly higher (P < 0.001) value than the value of 0.07 0.03 ng/ml found in patients without arrhythmia. Occurrence of arrhythmia could not be correlated with diagnosis, clinical status, cardiac size, blood gas, or serum electrolyte values. In 77 control subjects with ECG evidence of digoxin toxicity, mean serum digoxin level was 3.1 + 0.9 (SD) ng/ml. Since arrhythmia occurred at serum levels of digitalis lower than those observed in patients toxic to the drug who had not undergone cardiopulmonary bypass, and since the arrhythmia subsided as the serum level declined, and sKnce the levels were higher in patients who had arrhythmia postbypass than in those who did not, this study suggests that myocardial sensitivity to the toxic effects of digitalis is increased in the first 24 hours following cardiopulmonary bypass.
SUMMARY
To assess the possible role of digitalis in the etiology of arrhythmia following cardiopulmonary bypass, serum digoxin or digitoxin was determined serially by radioimmunoassay in 24 chronically digitalized patients undergoing open-heart surgery. After an initial fall during bypass probably secondary to intraoperative fluid, serum digitalis rebounded, rising to or surpassing the preoperative value in 21 of the 24 patients studied. Peak rebound serum digitalis occurred an average of 13 hours following onset of bypass. Eight patients receiving maintenance digoxin developed arrhythmia postbypass at or near the peak of the rebound. The arrhythmia subsided as the peak was passed. Mean serum digoxin at the time of arrhythmia was 1.3 0.2 (SD) ng/ml. A significantly higher (P < 0.001) value than the value of 0.07 0.03 ng/ml found in patients without arrhythmia. Occurrence of arrhythmia could not be correlated with diagnosis, clinical status, cardiac size, blood gas, or serum electrolyte values. In 77 control subjects with ECG evidence of digoxin toxicity, mean serum digoxin level was 3.1 + 0.9 (SD) ng/ml. Since arrhythmia occurred at serum levels of digitalis lower than those observed in patients toxic to the drug who had not undergone cardiopulmonary bypass, and since the arrhythmia subsided as the serum level declined, and sKnce the levels were higher in patients who had arrhythmia postbypass than in those who did not, this study suggests that myocardial sensitivity to the toxic effects of digitalis is increased in the first 24 hours following cardiopulmonary bypass.
Additional Indexing Words:
Serum digoxin Serum digitoxin Digitalis toxicity Open-heart surgery t-jA HERE is considerable uncertainty about the use of digitalis in patients undergoing cardiopulmonary bypass. Clinical experience has suggested that some individuals exhibit increased sensitivity to digitalis in the early postbypass period, but objective data have heretofore been lacking. Results from animal studies, performed largely in dogs with normal hearts, have been conflicting. Both increased" 2 and decreased3 sensitivity to the toxic effects of digitalis following cardiopulmonary bypass have been described.
The present investigation was undertaken to assess the role of digitalis in the etiology of arrhythmia observed in the first 24 hours after cardiopulmonary bypass. Patients receiving digitalis were studied before, during, and after circulatory support. It was found that arrhythmias compatible with digitalis toxicity occurred at serum levels, determined by radioimmunoassay, which were lower than those observed in patients who were clearly toxic to the drug but had not undergone cardiopulmonary bypass. Furthermore, in patients with arrhythmia postbypass, the digoxin levels were higher than those who did not manifest abnornal rhythm. The data are interpreted as supporting the view that the myocardial threshold for adverse effects of digitalis on cardiac rhythm is lowered in the immediate postbypass period in man.
Methods
Radioimmunoassay of serum digoxin or digitoxin was performed using specific antibodies by a modification of the method described by Smith, Butler, and Haber. 4 5 In this method digoxin or digitoxin (Mann Research) is coupled to human serum albumin (Pentex Biochemicals) in the presence of periodate as described by Butler and Chen.6 Specific antibodies are developed in New Zealand white rabbits following initial toe pad injections and repeated intramuscular, subcutaneous, and intraperitoneal injection every 2 weeks of 0.5 ml of human serum albumin-digoxin or human serum albumindigitoxin emulsified with Freund's adjuvant (Difco Labs).
Inhibition studies showed that the digoxin antibody bound digoxin approximately 30 times more actively than digitoxin on an equimolar basis. The digitoxin antibody bound digitoxin approximately nine times more actively than digoxin. Other specificity studies (table 1) indicated that the binding of the respective antibody to digoxin or digitoxin was not affected by compound F, progesterone, pregnanetriol, testosterone, estradiol, spironolactone, methylprednisolone, mannitol, heparin, or protamine, except at concentrations markedly exceeding physiologic and therapeutic levels. However, binding of digitoxin to the specific antibody was inhibited by digitoxigenin and digitoxigenin bisdigitoxoside (C. F. Boehringer & Soehne GmbH).
Serum for radioimmunoassay determination was obtained from blood which was centrifuged immediate-ly after withdrawal at 10,000 rpm for 20 min at 4°C. Blood for assay was withdrawn at least 6 hours after the administration of digitalis. All samples from a given patient were frozen at -20°C and analyzed in the same batch. Freezing a sample for as long as 6 months does not alter the assay. For the digoxin assay, 1 ml of serum, 100 ,gliters of antibody (3032/58 at a dilution of 1:15,000) and 1.9 ng of digoxin-12 alpha-H3 (New England Nuclear) were employed. For the digitoxin assay, 50 ,liters of serum, 100 ,uliters of specific antibody (3045/93 at a dilution of 1:12,000) and 1.1 ng of digitoxin-H3 (New England Nuclear) were utilized. These concentrations of antibody and ligand resulted in an initial binding of approximately 45% and excellent sensitivity in the 0.2-2.0 ng/ml range for digoxin, and in the 5-40 ng/ml range for digitoxin.
Duplicate samples were counted in a liquid scintillation medium composed of p-dioxane, methanol, napthalene (scintillation grade, Eastman Kodak), and butyl-PBD in toluene (Amersham/Searle). This medium has been shown to be 10% more efficient for counting tritiated digoxin and digitoxin than Bray's One standard deviation of the digoxin assay for 200 separate determinations of a sample with known concentration of 1.0 ng/ml was ± 0.11 ng/ml. The SD of 30 analyses of a blood sample containing digoxin run in the same batch was + 0.05 ng/ml. One standard deviation of the digitoxin assay for 150 separate determinations of a sample with a known concentration of 25 ng/ml was ± 2.0 ng/ml. The SD of 30 samples of a blood sample containing digitoxin run in the same batch was + 1.2 ng/ml. Arterial blood gas and pH determinations were performed on an Instrument Laboratories model 313 machine with standardization of the electrodes before each determination. Serum potassium determinations were performed by standard-flame photometry on an Instrument Laboratories model 143 photometer. Serum magnesium determinations were obtained by atomic absorption spectrophotometry (Perkin-Elmer Model 214).
Bypass was performed in a similar manner in all patients utilizing a Bentley Temptrol oxygenator. The pump was primed with 1500 ml of 5% dextrose and water and 50 g of mannitol. Body temperature during bypass was maintained between 28 and 34°C.
For the purposes of this study, arrhythmia was defined as one or more of the disturbances in impulse formation or conduction listed in table 2. Isolated atrial, nodal, or ventricular premature contractions were discounted as were episodes of wandering atrial pacemaker. The arrhythmias observed in nine patients after bypass were sustained, lasting from 90 min to 10 hours (mean duration: 3.2 hours).
Clinical Studies
Twenty patients receiving maintenance digoxin and four patients receiving maintenance digitoxin were studied. Nine underwent aortic valve replacement, eight mitral valve replacement, six vein bypass for coronary artery disease, and one patient had an openmitral valvulotomy. All patients were evaluated by the Table 2 Criteria for Digitalis Toxicity Presence of one or more:
1. Secondor third-degree atrioventricular block 2. Supraventricular tachycardia with block 3. Atrial fibrillation at a slow rate (less then 50) and ventricular premature complexes 4. Atrioventricular dissociation 5. Nodal (junctional) tachycardia 6. Multifocal ventricular premature complexes (10 or more per minute) 7. Ventricular bigeminy 8. Ventricular tachycardia Plus disappearance of arrhythmia when digitalis was withheld.
Circu#ation, Volume XLVII, Febfuary 1973 same physician (J.M.) and assigned a preoperative functional classification according to New York Heart Association criteria. Each had been receiving a fixed daily maintenance dosage of digoxin or digitoxin from 3 months to 4 years prior to surgery. The standard surgical policy at this institution is to discontinue digitalis the day before the operative procedure. However, three patients received digoxin the day before surgery due to medication error. No patient received digitalis the day of the operative procedure or in the first 24 hours following the procedure.
Serum for digitalis assay was obtained immediately prior to the start of bypass, at % hour intervals during bypass, and at 1-3 hour intervals for 24 hours following the cessation of bypass. Simultaneously, blood samples were obtained for arterial P02, pH, PCO2, potassium, and magnesium. An electrocardiogram was obtained when the patient arrived in the recovery room and monitoring was continuous thereafter with a physician in attendance in the room.
Results
The changes in serum digitalis during and in the early hours following cardiopulmonary bypass are summarized in tables 3 and 4 together with the operative procedure, total bypass time, amount of fluid and blood administered during bypass, and the arterial P02, pH, serum potassium, and magnesium obtained at the peak of the postbypass rebound in serum digitalis.
Serum Digoxin
After an initial fall reflecting dilution by the large volume of intraoperative fluid administered, serum digoxin underwent a postbypass rebound reaching (three patients) or exceeding (14 patients) the prebypass level in all but three of the subjects studied. The peak postbypass level occurred from 3 to 21 hours after the onset of pump perfusion. Eight patients (table 3) developed an arrhythmia at or near the peak of this postbypass rebound. In all, the arrhythmia subsided as serum digoxin subsequently fell.
The course of a 62-year-old patient (L.G.) who underwent mitral valve replacement is presented in figure 1 . During bypass serum digoxin fell to 0.8 ng/ml after a pump prime of 800 ml and administration of 3400 ml of blood and fluid. In the first 8 hours following bypass serum digoxin rose to 1.5 ng/ml. Coincident with the peak postoperative serum digoxin value, the rhythm changed from atrial fibrillation to atrial tachycardia. Blood gases, pH, and electrolytes remained stable and within normal limits. As the serum digoxin concentration subsequently declined, the tachycardia subsided and atrial fibrillation reappeared. The course of a 52-year-old patient (E.C.) who underwent aortic valve replacement is depicted in figure 2 . Serum digoxin fell from a prebypass value of 1.9 ng/ml to 0.9 ng/ml postoperatively. In the ensuing hours postoperatively, the serum digoxin rose to a peak of 1.4 ng/ml and nodal tachycardia developed. Later as the level of serum digoxin declined, sinus rhythm returned. Two days postbypass, while receiving maintenance digoxin in the face of an elevated blood urea nitrogen, nodal tachycardia returned. Serum digoxin at this time had risen to 3.0 ng/ml. Digoxin was withheld and, 24 hours later, when the serum level was 2.2 ng/ml, sinus rhythm returned. Thus, a rhythm interpreted as evidence for digoxin intoxication appeared at a serum value of only 1.4 ng/ml 18 hours postbypass, and recurred 2 days after operation at a level of 3.0 ng/ml. When the serum digoxin data are analyzed according to the presence or absence of arrhythmia postbypass, significant differences became apparent. Patients with arrhythmia interpreted as compatible with digitalis toxicity within the first 24 hours after cardiopulmonary bypass had significantly higher serum digoxin values prior to, during, and after circulatory support ( fig. 3 ). Prior to bypass, mean serum digoxin was 0.6 ± 0.2 ng/ml in the 12 patients who subsequently had no arrhythmia, and averaged 1.2 ± 0.3 ng/ml in the eight patients with arrhythmia (P < 0.001). During bypass mean serum digoxin fell to 0.4 + 0.2 ng/ml in patients without arrhythmia, and was 0.7 + 0.2 ng/ml in the patients with abnormal rhythm (P < 0.01). Peak postbypass serum digoxin was 0.7 ± 0.3 ng/ml in patients without arrhythmia, and 1.3 + 0.2 ng/ml in the patients with abnormal rhythm (P < 0.001).
Other factors could not be correlated with the presence or absence of postbypass arrhythmia. Thus no significant differences were found between the two groups in preoperative functional classification, age, cardiac size preor postoperative serum potassium, magnesium, pH, PCO2, P02, volume of intraoperative fluid, or duration bypass ( . 4 ).
Serum Digitoxin
Four patients receiving maintenance digitoxin who underwent cardiopulmonary bypass were studied. Each displayed a postbypass rebound in serum level after an initial intraoperative fall (table 4). One patient (M.M.) developed A-V dissociation 12 hours after bypass at a serum digitoxin level of 34 ng/ml.
Normal and Toxic Range of Serum Digoxin and Digitoxin
To determine the normal range of serum digoxin and the level at which toxic arrhythmias may occur, data were analyzed from patients receiving standard doses of the drug daily who did not undergo operative procedures.
In 103 patients receiving 0.25 mg of digoxin daily, mean serum level averaged 0.9 0.4 ng/ml (range 0.2-1.8 ng/ml). In 31 patients receiving 0.25 Circulation, Volume XLVII, February 1973 mg of digoxin twice daily, mean serum digoxin was 1.2 ± 0.5 ng/ml (range 0.3-2.6 ng/ml). In both groups, serum urea nitrogen and creatine were within normal limits. Urea nitrogen was < 18 mg/ 100 ml plasma and creatinine < 1.3 mg/100 ml plasma. In 77 patients deemed toxic to digitalis according to criteria described-previously (table 2), serum digoxin at the time of arrhythmia was 2.0-6.0 ng/ml. None of the patients with toxic arrhythmia had acute myocardial infarction, chronic lung disease, or myocardiopathy, conditions which may alter the myocardial sensitivity to toxic effects of digitalis. 9 12 In the patients with digoxin toxicity, arterial P02 averaged 79 mm Hg (range 54-94 mm Hg) and serum potassium ranged from 3.5 to 5.0 mEq/liter. In 105 patients receiving 0.1 mg of digitoxin daily, the mean serum level of the drug was 24 ± 7 ng/ml. In 36 patients with evidence of digitalis intoxication, serum digitoxin was above 40 ng/ml, ranging from 41 to 99 ng/ml. None of the patients with digitoxin toxicity had acute myocardial infarction, chronic lung disease, or myocardiopathy. From these data we conclude that in the first 24 hours following cardiopulmonary bypass, arrhythmias which appear to reflect toxic manifestations of digoxin and digitoxin occur at serum levels lower than those commonly observed in patients not subjected to operative procedures who have been diagnosed clinically as suffering from digitalis toxicity. Moreover, patients who developed arrhythmia postbypass have higher digitalis levels before, during, and after the procedure than those subjects who maintained normal rhythm. These observations siVggest the possibility that the myocardial toxic threshold to digitalis is reduced in the immediate postbypass period.
Discussion
Doherty first suggested the possible usefulness of a serum digoxin assay and showed, using tritiated digoxin, that serum concentrations obtained 6-8 hours after an administered dose reflect myocardial concentration in human subjects.'3 14 Development of a digoxin-specific antibody by Butler and Chen6 and demonstration of the clinical usefulness of a digitalis radioimmunoassay by Smith et al.4' 15 has made available a rapid and precise technic for studying serum digitalis pharmacokinetics.
Although the great majority of patients undergoing cardiopulmonary bypass receive maintenance digitalis prior to surgery, there has heretofore been little information available relating dosage, blood levels, and clinical events in the early postoperative period. Arrhythmia is common following open-heart surgery, but evaluation of possible causes may be difficult in the absence of objective data.
An increased susceptibility to the toxic effects of acetylstrophanthidin has been described in the first few hours following cardiopulmonary bypass in the undigitalized dogs.3 In chronically digitalized animals the threshold for acetylstrophanthidin-induced arrhythmia in the early postbypass period has been reported as either increased, unchanged, or reduced.", 2 These varied findings may depend in part upon whether or not the experimental animals displayed a postbypass rebound in serum digitalis level and the timing of administration of additional doses of acetylstrophanthidin.
Data from both experimental animals and man indicate that myocardial digoxin concentration is unchanged or slightly decreased at the end of cardiopulmonary bypass. '6-19 Our findings are in accord with these reports. The lowest serum levels did not occur until 1-3 hours following cessation of bypass in most of our patients. This observation probably reflects the fluid and metabolic readjustments which continue for some time after a normal circulatory mechanism is restored. Our data show that serum digoxin then gradually increased or rebounded to or exceeding the preoperative value although no further drug was administered. It is possible that during this period digoxin may be moving from blood into myocardium. Mechanisms involved in the postbypass rise in serum digitalis concentration in the absence of further dosage of the drug are not completely understood. Coltart et al.20 found an early postbypass rise in the mean plasma digoxin concentration in 11 chronically digitalized patients undergoing cardiopulmonary bypass. Doherty2' administered tritiated digoxin acutely to dogs who underwent bypass and found a reduction in half-life in the first 24 hours following bypass, suggesting altered Circulation, Volume XLVII, February 1973 metabolism or excretion of the drug. Since digoxin is largely excreted by the kidney, alteration in renal function during and after bypass may contribute to the failure of digoxin in the blood to decline at a normal rate postoperatively. This explanation would not apply to the patients receiving digitoxin, although altered intestinal or biliary excretion could influence postoperative levels. 22 Patients with preoperative congestive heart failure exhibit marked increases in extracellular fluid after bypass.23 This mechanism could contribute to the early postoperative fall in blood digoxin. However, we found no correlation between change in serum hematocrit, urine output, or administered fluid and the postoperative serum digoxin level. It is unlikely, therefore, that simple shifts in plasma volume can account for the observed postoperative changes in serum digoxin concentration. Graphic course of a 52-year-old patient (E.C.) who underwent aortic valve replacement. Data depicted as in fgure 1. Note that serum digoxin rose to a peak of 1.4 ng/ml 18 hours following bypass and nodal tachycardia developed. Two days after operation (not shown) nodal tachycardia recurred when serum level was 3.0 ng/ml after additional doses of digoxin in the face of rising blood urea nitrogen.
Many abnormalities have been implicated in the genesis of arrhythmias which commonly occur following bypass.24 In the present study, multiple factors were analyzed, and the only consistent finding was the fact that the serum digoxin concentration was significantly higher in the eight patients who developed arrhythmia postoperatively than in the 12 who did not. The arrhythmias occurred 6-16 hours following bypass, when myocardial alterations secondary to hypothermia and the bypass procedure were subsiding, yet serum and presumably myocardial digitalis concentrations were rising. Serum potassium and blood urea nitrogen remained unchanged and the arrhythmias subsided spontaneously. Despite the low serum levels we suggest that the arrhythmias were due to a toxic effect of digitalis possibly secondary to an alteration of myocardial toxic threshold.
An apparent decrease in the myocardial sensitivity to the toxic effects of digitalis has been recognized in several conditions. Kumar et al. observed in dogs that the amount of acetylstrophanthidin necessary to produce arrhythmia decreased by 24% in the first hours after myocardial infarction. 25 Harrison demonstrated in dogs that the dosage of acetylstrophanthidin necessary to produce ventricular tachycardia was reduced 19% during hypoxia when the average arterial P02 was lowered to 40 mm Hg. 26 Severe hypokalemia and hypomagnesia are widely recognized as increasing the sensitivity of the heart to arrhythmia in the presence of digitalis. 24 We have shown in man an apparent increased sensitivity to the toxic effects of digitalis in the first 24 hours after acute infarction9 and in the presence of severe hypoxia. 10 Although arterial PO was reduced in our patients who displayed postbypass arrhythmia while breathing room air, all were maintained on oxygen by endotracheal tube or face mask, and the mean arterial P02 of 82 mm Hg did not differ Patients with arrhythmia had higher mean serum digoxin before, during, and after circulatory support. Differences between means are highly significant. Arrhythmia occurred postbypass at serum digoxin levels below usual toxic threshold. significantly from the mean value (79 mm Hg) observed in the patients toxic to digitalis who had not undergone bypass. Rapid postbypass fluctuations of serum potassium are known to be associated with arrhythmia;27 however, none of the patients in this study experienced such changes since serum potassium was held within a relatively narrow range postbypass. It is not possible to evaluate the role of regional myocardial ischemia, intermittent hypoxia, or shifts of intracellular ions in the genesis of arrhythmia in the patients observed in the present study. It should be emphasized that the arrhythmias occurred postbypass at serum digoxin concentrations significantly below the level defined in our laboratory as compatible with digitalis toxicity in patients who presumably had a normal myocardial sensitivity to the drug. The rate of change of blood concentration of digoxin was slow postoperatively, and if serum levels were a reasonably accurate Circulation, Volume XLVII, February 1973 reflection of myocardial concentration,14 the data are interpreted to suggest that there was increased sensitivity of the heart to certain adverse effects of digitalis in the early postcardiopulmonary bypass period. The mechanism for such a change is not known but is undoubtedly at least in part secondary to the profound alterations in myocardial ion flux and metabolism known to occur during and after cardiopulmonary bypass. 29 The results of this study indicate that a preoperative assay of serum digitalis may be a useful adjunct to other measurements such as arterial blood gases, pH, and serum potassium in the interpretation of causative factors if arrhythmia develops during the first 24 hours after cardiopulmonary bypass. If the preoperative value of digoxin is 1.2 ng/ml or higher, and arrhythmia appears, a toxic effect of digitalis may be suspected. Knowledge of the prebypass serum digitalis together with an appreciation that a postbypass rebound in Serum digoxin in four patients undergoing thoracotomy pulmonary bypass. serum, and presumably myocardial, digitalis concentration will occur in some patients should permit a more rational approach to therapy. While small doses of digoxin (0.125 mg i.v.) are sometimes necessary to control rapid atrial fibrillation in the early postbypass period, caution is urged in the use of larger doses, particularly during the rebound phase. The value of this analysis is illustrated in figure 5 which depicts the course of a 54-year-old patient who underwent mitral valve replacement. During the postbypass rebound, digoxin 0.25 mg was administered intravenously to control a rapid ventricular rate due to atrial fibrillation. Serum digoxin rose to levels known to be toxic in nonsurgical patients and nodal tachycardia developed which persisted for 10 hours. This experience as well as others suggests that incautious use of digitalis in the early postoperative period may contribute to serious persistent arrhythmia and possibly to death. Graphic course of a 54-year-old patient who underwent mitral valve replacement and developed digitalis toxicity in early postoperative period. Shaded horizontal column indicates duration of pump run. Data depicted as in figure 1 . Because of rapid atrial fibrillation additional digoxin was administered intravenously but patient had developed an unrecognized nodal tachycardia. Nodal tachycardia was unremitting, and was followed by ventricular extrasystoles, ventricular tachycardia, and cardiac arrest. Digoxin level rose above toxic threshold prior to arrest.
